低剂量干扰素联合利巴韦林治疗丙肝代偿期肝硬化的临床分析

Clinical Analysis of Low Dose Interferon Combined With Ribavirin in the Treatment of Decompensated Hepatitis C Cirrhosis

目的探讨低剂量干扰素联合利巴韦林治疗丙肝代偿期肝硬化的效果。方法将96例丙肝代偿期肝硬化患者随机分为研究组(低剂量干扰素+利巴韦林)与对照组(利巴韦林)。结果研究组HCV-RNA阴转率、ALT复常率、持续病毒学应答率均优于对照组(P<0.05);研究组不良反应发生率低于对照组(P<0.05)。结论低剂量干扰素联合利巴韦林治疗丙肝代偿期肝硬化的效果明确。

Objective Study of low dose interferon combined with ribavirin in the treatment of decompensated hepatitis C cirrhosis effect. Methods Will 96 cases of hepatitis C patients with compensated liver cirrhosis were randomly divided into study group（low dose interferon plus ribavirin） and control group（ribavirin）. Results HCV-RNA negative conversion rate, ALT level, and sustained viral response rate in the study group were better than those in the control group（P〈0.05）; the incidence of adverse reactions in the study group was lower than that in the control group（P〈0.05）.Conclusion Low doses of interferon combined with ribavirin in the treatment of decompensated hepatitis C cirrhosis of the effect.